Navigation Links
Tip sheet for journalists: Equol, soy, menopause and bone health research published in Journal of Nutrition
Date:7/8/2010

eased . Subsequently, isoflavones and soyfoods have been studied for their ability to lower cholesterol, their potential as alternatives to conventional hormone therapy, alleviate, as well as treat hot flashes and inhibit bone loss in postmenopausal women.

"A Brief Historical Overview of the Past Two Decades of Soy and Isoflavone Research," Mark Messina, Ph.D., adjunct associate professor of nutrition at the Loma Linda University School of Public Health in California and of Nutrition Matters, Inc. in Port Townsend, Washington

2. Discovery and Chemistry of Equol

The health benefits of soy-based diets may be greater in people who can produce S-equol after eating soy, than in non-producers. Equol exists in two mirror-image forms: S- equol and R-equol, but intestinal bacteria exclusively produce the S-equol from soy, which is known to have a select affinity for estrogen receptor beta. A man-made chemical process is needed to make R-equol, which binds more weakly with a preference for estrogen receptor alpha. Both forms of equol are of interest from a clinical and pharmacological perspective and are under development as nutraceutical and pharmacological agents. The authors state that wide range of biological activities these two equol forms possess warrants their investigation for the treatment of a number of hormone-related conditions involving conditions dependent on the female hormone estrogen and related to the male hormone androgen.

"Equol: History, Chemistry and Formation," Kenneth D. R. Setchell, of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and Carlo Clerici of Clinica di Gastroenterologia ed Epatologia, at the Universita` degli Studi di Perugia University of Perugia in Italy

3. Biological Actions of Equol

Equol exhibits a wide range of biological properties. This paper reviews previous research on how the body processes both equol forms
'/>"/>

Contact: Stephen McCauley
smccauley@porternovelli.com
202-973-3615
Porter Novelli
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. BioScience tip sheet, October 2008
2. SNM releases new fact sheet on breast cancer and molecular imaging
3. BioScience tip sheet, November 2008
4. BioScience tip sheet, December 2008
5. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
6. BioScience tip sheet, January 2009
7. BioScience tip sheet, February 2009
8. BioScience tip sheet, March 2009
9. Energy-harvesting rubber sheets could power pacemakers, mobile phones
10. Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue
11. Study finds genetic links to age of first menstrual period and menopause
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... biotechnological company, has presented at the CIC ... (Derio), the first DNA chip concerning diagnosis ... the discrimination between normal, steatosis and NASH ... a progressive disease of the liver of ...
... system is a marvel of versatility, creating a variety of ... To carry out these tasks, immune cells follow a career ... a report in the May 2005 issue of Immunity, Fox ... Ph.D. and Dietmar J. Kappes, Ph.D., show that cell-receptor signaling ...
... of the National Institutes of Health, have built the ... Scientists searching for genes that go awry and cause ... point of reference because it pinpoints which genes are ... normal conditions, without known disease. , Scientists can compare ...
Cached Biology News:Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3Gov't Creates Gene Database of Normal Human Tissues 2Gov't Creates Gene Database of Normal Human Tissues 3Gov't Creates Gene Database of Normal Human Tissues 4
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5